CN103285324A - Medicine composition for treating phlebitis - Google Patents
Medicine composition for treating phlebitis Download PDFInfo
- Publication number
- CN103285324A CN103285324A CN2013102177853A CN201310217785A CN103285324A CN 103285324 A CN103285324 A CN 103285324A CN 2013102177853 A CN2013102177853 A CN 2013102177853A CN 201310217785 A CN201310217785 A CN 201310217785A CN 103285324 A CN103285324 A CN 103285324A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- phlebitis
- erythromycin
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicine composition for treating phlebitis. The medicine composition is made from the following medicines in parts by weight: 10-25 parts of golden yellow powder and 8-15 parts of erythromycin ointment. A preparation method of the medicine composition comprises the steps of respectively weighing the golden yellow powder and the erythromycin ointment in a certain parts by weight, taking the erythromycin ointment as an oil base, uniformly mixing the two medicines and obtaining the paste medicine composition. The medicine composition disclosed by the invention has the advantages that the raw materials are conveniently available, the composition preparation is simple and low in cost and the treatment effect is far better than the effect of using the golden yellow powder alone; the efficacies of stopping pain, removing stasis, activating blood and diminishing swelling on chemotherapeutic phlebitis, mechanical phlebitis and phlebitis caused by common intravenous infusion exosmosis are provided, edema of most of patients disappears within 24 hours after use and the red and the heat discomfort disappears within 72 hours; allergy symptoms have small possibility of generation and the use is convenient.
Description
Technical field
The present invention relates to the pharmaceutical technology field, specifically, is a kind of phlebitic pharmaceutical composition for the treatment of.
Background technology
Phlebitis refers to the vein blood vessel inflammation, and according to the diseased region difference, phlebitis can be divided into superficial phlebitis and deep phlebitis.Its pathology alter vascellum endometrial hyperplasia, tube chamber narrows down, slow blood flow.Surrounding skin can present congestive erythema, sometimes with edema.Superficial phlebitis patient sick lower limb vein redness, pain increase the weight of during walking, can touch pain sex cords shape runner or beading sample tuberosity.The deep phlebitis person falls ill suddenly, suffers from limb and is pitting swelling, and skin is kermesinus, and venous engorgement or varicose and telangiectasis are widely arranged; Later stage malnutrition occurs and sexually revises, and with the stasis of blood long-pending dermatitis, pigmentation or skin ulcer, thigh, shin Zhou Jing are good for more than the thick 1cm of limb, swell and ache during walking and increase the weight of, and alleviates after reposing, and as seen phlebography suffers from the narrow or obstruction of limb deep vein pipe.Cause that phlebitic reason has: material, length and the caliber of (1) catheter needle is excessive or too small, operating technology is bad; (2) unsuitable site of puncture; (3) time of catheter needle indwelling is oversize; (4) fixing means is improper; (5) Shu Ye concentration is too big, Acidity of Aikalinity is too strong or the incompatible precipitation that causes; (6) the Pathophysiology situation of sufferer itself causes blood vessel wall fragility, inflammation as age or disease; (7) osmotic pressure is bigger; (8) the transfusion speed is improper.
Intravenously administrable is the most frequently used administering mode of antitumor drug, tend to occur chemotherapeutic phlebitis in the administration process, so-called chemotherapeutic phlebitis is because cancer therapy drug reacts the aseptic inflammation that the direct stimulation of blood vessel causes, is the very common toxic reaction of intravenous injection cancer therapy drug.Because wrongful fixing means such as site of puncture are not fixed, cause the slip of needle tubing; Or the conduit caliber of selecting for use is too thick, stimulates blood vessel wall; Or the too close joint in site of puncture, owing to causing needle tubing and blood vessel wall constantly to rub, joint motion produces inflammatory response, can cause mechanicalness phlebitis.
Chinese patent application CN201210548426.1, open day on February 27th, 2013, disclose a kind of phlebitic pharmaceutical composition for the treatment of, described pharmaceutical composition is composed of the following components by ratio of weight and the number of copies: 1～2 part in 2～3 parts of Radix Angelicae Sinensis, 2～3 parts of Radix Notoginseng, 1～2 part of Radix Scutellariae, 1～2 part of Olibanum, 1～2 part of Myrrha, 1～2 part of Fructus Gardeniae, 1～2 part on Flos Carthami, 1～2 part of Radix Et Rhizoma Rhei, 1～2 part of Rhizoma Smilacis Glabrae and Radix Glycyrrhizae.But about the phlebitic pharmaceutical composition for the treatment of of the present invention, yet there are no report.
Summary of the invention
The objective of the invention is at deficiency of the prior art, a kind of phlebitic pharmaceutical composition for the treatment of is provided, especially at chemotherapeutic phlebitis and mechanicalness phlebitis.
For achieving the above object, the technical scheme taked of the present invention is:
A kind ofly treat phlebitic pharmaceutical composition, described pharmaceutical composition is made by following medicaments in part by weight: 10～25 parts of JINHUANG SAN, 8～15 parts of erythromycin ointments.
Described pharmaceutical composition is made by following medicaments in part by weight: 15～22 parts of JINHUANG SAN, 9～12 parts of erythromycin ointments.
Described pharmaceutical composition is made by following medicaments in part by weight: 20 parts of JINHUANG SAN, 10 parts of erythromycin ointments.
The main component of described JINHUANG SAN is: Rhizoma Curcumae Longae, Radix Et Rhizoma Rhei, Cortex Phellodendri, Rhizoma Atractylodis, Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae, Radix Glycyrrhizae, Arisaema Cum Bile, the Radix Angelicae Dahuricae and Radix Trichosanthis.
Described erythromycin ointment is to be main active with erythromycin, the ointment that is prepared from according to acceptable auxiliary on the pharmaceutics.
Described phlebitis is chemotherapeutic phlebitis.
Described phlebitis is mechanicalness phlebitis.
Described preparation of drug combination method is: taking by weighing JINHUANG SAN and the erythromycin ointment of certain part by weight respectively, is oil base with the erythromycin ointment, and two kinds of medicament mixed are even, is prepared into the pharmaceutical composition of paste.
The trade name of JINHUANG SAN claims ruyi jinhuang powder, ruyi jinhuang san again, and its description is labeled as external, for redness, dysphoria with smothery sensation, pain, transfers deposited with green tea; Swollen without a head for overflowing, transfer deposited with vinegar or Herba Alii fistulosi wine; Also available vegetable oil or Mel are transferred and are applied.Can use in 1st for several times.Main effect is heat-clearing and toxic substances removing, reducing swelling and alleviating pain.Be used for the pyretic toxicity stasis of blood and stagnate that furuncle swells and ache due to the skin, disease sees that skin is red, swollen, hot, bitterly, also can be used for traumatic injury.This medicine skin ulceration place forbidding of lay special stress on.
Erythromycin ointment is for infection and the acne vulgaris of suppurative dermatosis such as impetigo, small-area burn, ulcer surface, and its effective ingredient is erythromycin, and adjuvant is other excipient such as liquid paraffin, Yellow Vaselin.
The invention has the advantages that:
The raw material of pharmaceutical composition of the present invention obtains conveniently, and preparation of compositions is simple, and cost is low, and therapeutic effect is far superior to use separately JINHUANG SAN; This pharmaceutical composition all has pain relieving, blood stasis dispelling, invigorates blood circulation and subsides a swelling effect chemotherapeutic phlebitis, mechanicalness phlebitis, the common vein fluid infusion phlebitis that causes of exosmosing, use most patient's edema extinction after 24 hours, red after 72 hours, hot sense of discomfort disappears; Be difficult for producing allergic symptom, easy to use.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is elaborated.
Used JINHUANG SAN is available from the Tongrentang Pharmaceutical Factory, Beijing TongrenTang Co., Ltd among the embodiment, and its main component is: Rhizoma Curcumae Longae, Radix Et Rhizoma Rhei, Cortex Phellodendri, Rhizoma Atractylodis, Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae, Radix Glycyrrhizae, Arisaema Cum Bile, the Radix Angelicae Dahuricae and Radix Trichosanthis.Used erythromycin ointment is available from Shanghai General Pharmaceutical Co., ltd. among the embodiment, and its active component is erythromycin, and excipient is liquid paraffin and Yellow Vaselin.
Embodiment 1 preparation of drug combination (one)
Take by weighing 10 parts of JINHUANG SAN, 10 parts of erythromycin ointments place vessel, mix, and make the pharmaceutical composition ointment.
Embodiment 2 preparation of drug combination (two)
Take by weighing 10 parts of JINHUANG SAN, 15 parts of erythromycin ointments place vessel, mix, and make the pharmaceutical composition ointment.
Embodiment 3 preparation of drug combination (three)
Take by weighing 10 parts of JINHUANG SAN, 8 parts of erythromycin ointments place vessel, mix, and make the pharmaceutical composition ointment.
Embodiment 4 preparation of drug combination (four)
Take by weighing 15 parts of JINHUANG SAN, 8 parts of erythromycin ointments place vessel, mix, and make the pharmaceutical composition ointment.
Embodiment 5 preparation of drug combination (five)
Take by weighing 20 parts of JINHUANG SAN, 10 parts of erythromycin ointments place vessel, mix, and make the pharmaceutical composition ointment.
Embodiment 6 preparation of drug combination (six)
Take by weighing 20 parts of JINHUANG SAN, 13 parts of erythromycin ointments place vessel, mix, and make the pharmaceutical composition ointment.
Embodiment 7 preparation of drug combination (seven)
Take by weighing 25 parts of JINHUANG SAN, 8 parts of erythromycin ointments place vessel, mix, and make the pharmaceutical composition ointment.
Embodiment 8 preparation of drug combination (eight)
Take by weighing 25 parts of JINHUANG SAN, 15 parts of erythromycin ointments place vessel, mix, and make the pharmaceutical composition ointment.
The clinical practice of embodiment 9 pharmaceutical compositions
(JINHUANG SAN: erythromycin ointment=2:1 w/w) treats the phlebitis patient pharmaceutical composition that uses embodiment 5 to prepare, and uses JINHUANG SAN in contrast separately, the JINHUANG SAN of this independent medication sterilized water furnishing pasty state.
Therapeutic Method: with aseptic cotton carrier the medicine for preparing is applied to the phlebitis place during use, the scope of smearing is greater than extent of disease 3～4cm, and thickness 1～2mm covers with sterile gauze, changes dressings every day 2 times, and 7 days is a course for the treatment of.
In the efficacy assessment standard, cure: clinical symptoms such as red swelling of the skin burning pain all disappear, and the test chamber inspection is normal.Take a turn for the better: the red swelling of the skin burning pain disappears, clinical symptom relief, and the state of an illness is controlled, and lab testing improves or is normal.Do not heal: clinical symptoms does not have being clearly better or increases the weight of.
To clinical 260 routine phlebitis patients, comprise that superficial vein keeps somewhere chemotherapeutic phlebitis, the PICC that the input chemotherapeutics causes and put the mechanicalness phlebitis of top, site of puncture, pipe back or the phlebitis patient that a large amount of fluid infusion causes, carry out medication.Wherein picking 10 examples are organized in contrast at random, use the JINHUANG SAN treatment separately.After 1 course for the treatment of, efficacy result sees Table 1:
Table 1 phlebitis patient treatment situation
Use 250 philtrums of pharmaceutical composition of the present invention, have 1/3rd patient namely to cure in 3 days, the result shows that the therapeutic effect of pharmaceutical composition of the present invention is far superior to use separately JINHUANG SAN; This pharmaceutical composition all has pain relieving, blood stasis dispelling, invigorates blood circulation and subsides a swelling effect chemotherapeutic phlebitis, mechanicalness phlebitis, the common vein fluid infusion phlebitis that causes of exosmosing, use most patient's edema extinction after 24 hours, red after 72 hours, hot sense of discomfort disappears; Use the no irritated case in back, easy to use, effective percentage 100%.Use medicine composite for curing of the present invention again behind 9 people that matched group is not cured, all cure after 1 course for the treatment of.
The above only is preferred implementation of the present invention; should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the inventive method; can also make some improvement and replenish, these improvement and replenish and also should be considered as protection scope of the present invention.
Claims (8)
1. the phlebitic pharmaceutical composition for the treatment of is characterized in that described pharmaceutical composition is made by following medicaments in part by weight: 10～25 parts of JINHUANG SAN, 8～15 parts of erythromycin ointments.
2. pharmaceutical composition according to claim 1 is characterized in that, described pharmaceutical composition is made by following medicaments in part by weight: 15～22 parts of JINHUANG SAN, 9～12 parts of erythromycin ointments.
3. pharmaceutical composition according to claim 1 is characterized in that, described pharmaceutical composition is made by following medicaments in part by weight: 20 parts of JINHUANG SAN, 10 parts of erythromycin ointments.
4. according to the arbitrary described pharmaceutical composition of claim 1 to 3, it is characterized in that the main component of described JINHUANG SAN is: Rhizoma Curcumae Longae, Radix Et Rhizoma Rhei, Cortex Phellodendri, Rhizoma Atractylodis, Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae, Radix Glycyrrhizae, Arisaema Cum Bile, the Radix Angelicae Dahuricae and Radix Trichosanthis.
5. according to the arbitrary described pharmaceutical composition of claim 1 to 3, it is characterized in that described erythromycin ointment is to be main active with erythromycin, the ointment that is prepared from according to acceptable auxiliary on the pharmaceutics.
6. pharmaceutical composition according to claim 1 is characterized in that, described phlebitis is chemotherapeutic phlebitis.
7. pharmaceutical composition according to claim 1 is characterized in that, described phlebitis is mechanicalness phlebitis.
8. pharmaceutical composition according to claim 1, it is characterized in that described preparation of drug combination method is: taking by weighing JINHUANG SAN and the erythromycin ointment of certain part by weight respectively, is oil base with the erythromycin ointment, two kinds of medicament mixed are even, be prepared into the pharmaceutical composition of paste.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102177853A CN103285324A (en) | 2013-06-04 | 2013-06-04 | Medicine composition for treating phlebitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013102177853A CN103285324A (en) | 2013-06-04 | 2013-06-04 | Medicine composition for treating phlebitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103285324A true CN103285324A (en) | 2013-09-11 |
Family
ID=49087213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102177853A Pending CN103285324A (en) | 2013-06-04 | 2013-06-04 | Medicine composition for treating phlebitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285324A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012690A (en) * | 2014-02-27 | 2015-11-04 | 韩玉芳 | Medicine for treating mechanical phlebitis |
| CN114588239A (en) * | 2022-03-17 | 2022-06-07 | 魏定夏 | Composition for preventing and treating phlebitis, preparation method and application |
-
2013
- 2013-06-04 CN CN2013102177853A patent/CN103285324A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 刘继红: "《盖诺所致静脉炎的防治与护理进展》", 《临床护理杂志》 * |
| 郑妍; 晏丽: "《红霉素软膏治疗深静脉置管穿刺点周围皮肤感染95例》", 《解放军护理杂志》 * |
| 陈美华; 翁美芳: "《如意金黄散防治静脉炎研究进展》", 《中国乡村医药》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105012690A (en) * | 2014-02-27 | 2015-11-04 | 韩玉芳 | Medicine for treating mechanical phlebitis |
| CN105012691A (en) * | 2014-02-27 | 2015-11-04 | 韩玉芳 | Mechanical phlebitis treating medicine for external use |
| CN114588239A (en) * | 2022-03-17 | 2022-06-07 | 魏定夏 | Composition for preventing and treating phlebitis, preparation method and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104398640A (en) | Traditional Chinese medicinal composition for treating prostatitis, and preparation method thereof | |
| CN103611084B (en) | Ointment for treating sore and furuncle and preparation method thereof | |
| CN102961719B (en) | Medicament for treating intravertebral postanesthesia shivering | |
| CN104740023A (en) | Traditional Chinese medicine fuming and washing agent for treating edema of extremity induced by apoplectic hemiplegia | |
| CN103285324A (en) | Medicine composition for treating phlebitis | |
| CN103893701B (en) | A kind of Chinese medicine composition alleviating patients suffering from postoperative pain and promote wound healing | |
| CN102614324A (en) | Chinese medicinal synthetic preparation for assisting western medicines in treating phlebophlogosis | |
| CN102579549B (en) | Chinese medicinal balm for treating burns and scalds | |
| CN102526382B (en) | Plaster for relieving swelling and pain | |
| CN105816831B (en) | A kind of external application application therapy tremble with fear stasis of blood ostalgia Chinese medicine composition and preparation method and application | |
| CN104800427A (en) | Burn and scald recovery application and preparation method thereof | |
| CN103230479A (en) | Externally used ointment for treating bed sore and scalds and burns | |
| CN105709195A (en) | Traditional Chinese medicine paste for preventing and treating PICC phlebitis and phlebothrombosis | |
| CN101288760B (en) | Externally-used drug for treating appendicitis | |
| CN107041913B (en) | Traditional Chinese medicine composition for phlebitis caused by venous transfusion, spray and application | |
| CN104524017A (en) | Traditional Chinese medicine preparation for treating angiitis | |
| CN110731990A (en) | A Chinese medicinal oil for treating burn and scald | |
| CN104000885B (en) | A kind of liniment treating child vein inflammation | |
| CN104840624A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN1132588C (en) | Chinese patent medicine for treating gastrosis and its preparing process | |
| CN103349720A (en) | Traditional Chinese medicine composition for treating acute cystitis | |
| CN103385984A (en) | Traditional Chinese medicine composition for treating phlebitis | |
| CN114288374A (en) | Herbaceous plant preparation for treating blood stasis type cervical and lumbar diseases | |
| CN104337912A (en) | Externally-used Chinese herbal medicine treating pruritic skin disease and preparation method thereof | |
| CN109498692A (en) | A kind of Chinese herbal medicine and preparation method thereof for treating pruritus dermatopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130911 |